Published in N Engl J Med on January 04, 2007
Predicting new molecular targets for known drugs. Nature (2009) 9.71
Automated design of ligands to polypharmacological profiles. Nature (2012) 3.54
Engineering GPCR signaling pathways with RASSLs. Nat Methods (2008) 2.29
Platelet-derived serotonin links vascular disease and tissue fibrosis. J Exp Med (2011) 2.05
Structural basis for molecular recognition at serotonin receptors. Science (2013) 1.86
Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. J Natl Cancer Inst (2008) 1.71
Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists. Pituitary (2011) 1.50
Reducing safety-related drug attrition: the use of in vitro pharmacological profiling. Nat Rev Drug Discov (2012) 1.47
Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine(2B) receptor agonists: implications for drug safety assessment. Mol Pharmacol (2009) 1.44
Serotonin and blood pressure regulation. Pharmacol Rev (2012) 1.41
Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology (Berl) (2009) 1.28
Directed molecular evolution of DREADDs: a generic approach to creating next-generation RASSLs. Nat Protoc (2010) 1.26
Current approaches to the treatment of Parkinson's disease. Neuropsychiatr Dis Treat (2008) 1.19
How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines? Br J Pharmacol (2011) 1.19
Appetite suppressants, cardiac valve disease and combination pharmacotherapy. Am J Ther (2009) 1.17
Neurochemical profiles of some novel psychoactive substances. Eur J Pharmacol (2012) 1.15
5-HT(2B) receptors are required for serotonin-selective antidepressant actions. Mol Psychiatry (2011) 1.13
Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond. PLoS Pathog (2016) 1.11
Selective serotonin 5-HT(2C) receptor activation suppresses the reinforcing efficacy of cocaine and sucrose but differentially affects the incentive-salience value of cocaine- vs. sucrose-associated cues. Neuropharmacology (2011) 1.07
Dual dopamine/serotonin releasers: potential treatment agents for stimulant addiction. Exp Clin Psychopharmacol (2008) 1.06
Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action. J Med Chem (2009) 1.04
DREADDs: novel tools for drug discovery and development. Drug Discov Today (2013) 1.03
Shape signatures: new descriptors for predicting cardiotoxicity in silico. Chem Res Toxicol (2008) 1.01
Integrated Approaches for Genome-wide Interrogation of the Druggable Non-olfactory G Protein-coupled Receptor Superfamily. J Biol Chem (2015) 1.00
Serotonin receptors and heart valve disease--it was meant 2B. Pharmacol Ther (2011) 0.99
Effect of (-)-trans-PAT, a novel 5-HT2C receptor agonist, on intake of palatable food in mice. Pharmacol Biochem Behav (2008) 0.98
Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA). Br J Pharmacol (2008) 0.98
Lorcaserin, a 5-HT(2C) receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure. J Clin Endocrinol Metab (2010) 0.98
Prophylaxis of migraine: general principles and patient acceptance. Neuropsychiatr Dis Treat (2008) 0.98
Benfluorex and unexplained valvular heart disease: a case-control study. PLoS One (2010) 0.97
Irving Page Lecture: 5-HT(2A) serotonin receptor biology: interacting proteins, kinases and paradoxical regulation. Neuropharmacology (2011) 0.97
Fluoxetine-mediated 5-HT2B receptor stimulation in astrocytes causes EGF receptor transactivation and ERK phosphorylation. Psychopharmacology (Berl) (2008) 0.96
Serotonergic drugs and valvular heart disease. Expert Opin Drug Saf (2009) 0.96
HTS and rational drug design to generate a class of 5-HT(2C)-selective ligands for possible use in schizophrenia. ChemMedChem (2010) 0.94
Structure and function of serotonin G protein-coupled receptors. Pharmacol Ther (2015) 0.94
Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype-targeted drugs. J Clin Invest (2013) 0.93
Neural and cardiac toxicities associated with 3,4-methylenedioxymethamphetamine (MDMA). Int Rev Neurobiol (2009) 0.93
A serotonin-induced N-glycan switch regulates platelet aggregation. Sci Rep (2013) 0.92
Echocardiographic evidence for valvular toxicity of benfluorex: a double-blind randomised trial in patients with type 2 diabetes mellitus. PLoS One (2012) 0.90
Cardiac effects of MDMA on the metabolic profile determined with 1H-magnetic resonance spectroscopy in the rat. NMR Biomed (2009) 0.87
Valvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individuals. BMC Med (2008) 0.87
Life beyond kinases: structure-based discovery of sorafenib as nanomolar antagonist of 5-HT receptors. J Med Chem (2012) 0.86
Fenfluramine disrupts the mitral valve interstitial cell response to serotonin. Am J Pathol (2009) 0.85
Role of serotoninergic pathways in drug-induced valvular heart disease and diagnostic features by echocardiography. J Am Soc Echocardiogr (2009) 0.85
Serotonin produces monoamine oxidase-dependent oxidative stress in human heart valves. Am J Physiol Heart Circ Physiol (2009) 0.84
Molecular and behavioral pharmacology of two novel orally-active 5HT2 modulators: potential utility as antipsychotic medications. Neuropharmacology (2013) 0.83
Lorcaserin for the treatment of obesity. Drugs Today (Barc) (2010) 0.82
Clozapine augmentation with amisulpride. J Psychiatry Neurosci (2014) 0.82
Inflammatory regulation of valvular remodeling: the good(?), the bad, and the ugly. Int J Inflam (2011) 0.81
Dopamine receptors and Parkinson's disease. Int J Med Chem (2011) 0.81
Dopamine agonists and ischemic complications in Parkinson's disease: a nested case-control study. Eur J Clin Pharmacol (2011) 0.80
A novel drug discovery strategy: mechanistic investigation of an enantiomeric antitumor agent targeting dual p53 and NF-κB pathways. Oncotarget (2014) 0.79
Pharmacological profile of novel psychoactive benzofurans. Br J Pharmacol (2015) 0.79
The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial. Hum Reprod (2010) 0.79
High risk factors for valvular heart disease from dopamine agonists in patients with Parkinson's disease. J Neural Transm (Vienna) (2008) 0.79
Use of antidepressant serotoninergic medications and cardiac valvulopathy: a nested case-control study in the health improvement network (THIN) database. Br J Clin Pharmacol (2012) 0.77
Active metabolites as antidepressant drugs: the role of norquetiapine in the mechanism of action of quetiapine in the treatment of mood disorders. Front Psychiatry (2013) 0.77
Dopamine agonists and valvular heart disease. N Engl J Med (2007) 0.76
Predictive in silico studies of human 5-hydroxytryptamine receptor subtype 2B (5-HT2B) and valvular heart disease. Curr Top Med Chem (2013) 0.76
Pleuropulmonary Toxicity of Another Anti-Parkinson's Drug: Cabergoline. Open Respir Med J (2009) 0.76
Serotonin 2B Receptor Antagonism Prevents Heritable Pulmonary Arterial Hypertension. PLoS One (2016) 0.76
Structure-Based Scaffold Repurposing for G Protein-Coupled Receptors: Transformation of Adenosine Derivatives into 5HT2B/5HT2C Serotonin Receptor Antagonists. J Med Chem (2016) 0.76
Identification of host interactions for phenotypic antimalarial hits. J Cheminform (2014) 0.75
Impossible or merely difficult? Two grand challenges from a biologist's perspective. ACS Med Chem Lett (2013) 0.75
Benfluorex withdrawal in France: Still be hiding somewhere in the world? J Pharmacol Pharmacother (2011) 0.75
Dopamine agonists and valvular heart disease. N Engl J Med (2007) 0.75
A dynamic view of molecular switch behavior at serotonin receptors: implications for functional selectivity. PLoS One (2014) 0.75
Valvular heart disease in a patient taking 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'). Br J Clin Pharmacol (2012) 0.75
Fenfluramine-induced gene dysregulation in human pulmonary artery smooth muscle and endothelial cells. Pulm Circ (2011) 0.75
Dopamine agonists and valvular heart disease. N Engl J Med (2007) 0.75
Novel 4-substituted-N,N-dimethyltetrahydronaphthalen-2-amines: synthesis, affinity, and in silico docking studies at serotonin 5-HT2-type and histamine H1 G protein-coupled receptors. Bioorg Med Chem (2015) 0.75
Non-proliferative and Proliferative Lesions of the Cardiovascular System of the Rat and Mouse. J Toxicol Pathol (2016) 0.75
Acute pergolide exposure stiffens engineered valve interstitial cell tissues and reduces contractility in vitro. Cardiovasc Pathol (2016) 0.75
Advances in the Diagnosis, Treatment, and Molecular Genetics of Pituitary Adenomas in Childhood. US Endocrinol (2009) 0.75
Side effects of a dopamine agonist therapy for Parkinson's disease: a mini-review of clinical pharmacology. Yale J Biol Med (2016) 0.75
We Need 2C but Not 2B: Developing Serotonin 2C (5-HT2C ) Receptor Agonists for the Treatment of CNS Disorders. ChemMedChem (2015) 0.75
Design, Synthesis, and Evaluation of Tetrasubstituted Pyridines as Potent 5-HT2C Receptor Agonists. ACS Med Chem Lett (2015) 0.75
Antidepressants and Valvular Heart Disease: A Nested Case-Control Study in Taiwan. Medicine (Baltimore) (2016) 0.75
A short history of the 5-HT2C receptor: from the choroid plexus to depression, obesity and addiction treatment. Psychopharmacology (Berl) (2017) 0.75
Ergot and non-ergot dopamine agonists and heart failure in patients with Parkinson's disease. Eur J Clin Pharmacol (2016) 0.75
How Ligands Illuminate GPCR Molecular Pharmacology. Cell (2017) 0.75
Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med (2007) 6.23
Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med (2007) 5.95